Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Evidences regarding the efficacy of different antibiotic regimens proposed for treatment of multidrug‑resistant (MDR) Gram‑negative pathogens have been reviewed. Available data in Scopus, Medline, EMBASE, the Cochrane central register of controlled trials, and Cochrane database of systematic reviews have been collected. Several antibiotic regimens are proposed for treatment of MDR Gram‑negative infections (defined as nonsusceptibility to at least one agent in three or more antimicrobial categories). The most challenging issue is the treatment of carbapenem‑resistant (CR) Gram‑negative pathogens. A carbapenem plus either colistin or tigecycline was the most effective regimen for treatment of CR Gram‑negative pathogens with low‑level resistance (minimal inhibitory concentration [MIC] ≤ 8 mg/L). However, in high‑level resistance (MIC > 8 mg/L), combination of colistin and tigecycline showed promising effect.
Cloete TE. Resistance mechanisms of bacteria to antimicrobial compounds. Int Biodeterior Biodegradation 2003;51:277‑82. 2. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med 2006;119:S3‑10. 3. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008;197:1079‑81. 4. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem‑resistant Gram‑negative bacteria. Expert Rev Anti Infect Ther 2013;11:1333‑53. 5. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug‑resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71‑93. 6. Livermore DM, Woodford N. Carbapenemases: A problem in waiting? Curr Opin Microbiol 2000;3:489‑95. 7. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: A new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3:541‑8. 8. Queenan AM, Bush K. Carbapenemases: The versatile beta‑lactamases. Clin Microbiol Rev 2007;20:440‑58. 9. Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Curr Opin Pharmacol 2014;18:56‑60. 10. Paterson DL. Resistance in gram‑negative bacteria: Enterobacteriaceae. Am J Infect Control 2006;34:S20‑8. 11. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug‑resistant, extensively drug‑resistant and pandrug‑resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268‑81. 12. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended‑spectrum ß‑lactamases: A systematic review and meta‑analysis. J Antimicrob Chemother 2012;67:2793‑803. 13. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem‑resistant Enterobacteriaceae infections. Emerg Infect Dis 2014;20:1170‑5. 14. Maragakis LL, PerlTM. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254‑63. 15. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug‑resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008‑11. 16. SobieszczykME, FuruyaEY, HayCM, PancholiP, Della‑LattaP, Hammer SM, et al. Combination therapy with polymyxin B for the treatment of multidrug‑resistant Gram‑negative respiratory tract infections. J Antimicrob Chemother 2004;54:566‑9. 17. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug‑resistant Gram‑negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136‑46. 18. Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, et al. Rifampicin/imipenem combination in the treatment of carbapenem‑resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2006;58:697‑700. 19. Tseng YC, Wang JT, Wu FL, Chen YC, Chie WC, Chang SC. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007;59:181‑90. 20. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem‑resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369‑75. 21. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem‑resistant Klebsiella pneumoniae in critically ill patients: A prospective evaluation. Clin Microbiol Infect 2010;16:184‑6. 22. GoundenR, Bamford C, van Zyl‑SmitR, Cohen K, Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi‑drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009;9:26. 23. Tsioutis C, Kritsotakis EI, Maraki S, Gikas A. Infections by pandrug‑resistant gram‑negative bacteria: Clinical profile, therapeutic management, and outcome in a series of 21 patients. Eur J Clin Microbiol Infect Dis 2010;29:301‑5. 24. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High‑dose, extended‑interval colistin administration in critically ill patients: Is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012;54:1720‑6. 25. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, et al. Carbapenem‑sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase‑producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013;56:697‑700. 26. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka‑Graphakos E, et al. Infections caused by carbapenem‑resistant Klebsiella pneumoniae among patients in intensive care units in Greece: A multi‑centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014;20:O117‑23. 27. Balandin Moreno B, Fernández Simón I, Pintado García V, Sánchez Romero I, Isidoro Fernández B, Romera Ortega MA, et al. Tigecycline therapy for infections due to carbapenemase‑producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis 2014;46:175‑80.
28. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug‑resistant and extensively drug‑resistant carbapenemase‑producing Gram‑negative bacteria. Int J Antimicrob Agents 2014;43:52‑9. 29. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, et al. Nosocomial multi‑drug resistant Acinetobacter baumannii blood stream infection: Risk factors and outcome with ampicillin‑sulbactam treatment. J Hosp Infect 2003;54:32‑8. 30. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY,et al. Multidrug‑resistant Acinetobacter baumannii bacteraemia: Clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007;13:196‑8. 31. Choi JY, Kim CO, Park YS, Yoon HJ, Shin SY, Kim YK, et al. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia. Yonsei Med J 2006;47:63‑9. 32. Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, SkoutelisA, et al. Prospective observational study of the impact of VIM‑1 metallo‑beta‑lactamase on the outcome of patients with Klebsiella pneumoniae blood stream infections. Antimicrob Agents Chemother 2009;53:1868‑73. 33. Lim SK, Lee SO, Choi SH, Choi JP, Kim SH, Jeong JY, et al. The outcomes of using colistin for treating multidrug resistant Acinetobacter species blood stream infections. J Korean Med Sci 2011;26:325‑31. 34. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, et al. Treatment and outcomes in carbapenem‑resistant Klebsiella pneumoniae blood stream infections. Diagn Microbiol Infect Dis 2011;69:357‑62. 35. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in blood stream infections caused by Klebsiella pneumoniae carbapenemase‑producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012;55:943‑50. 36. ZarkotouO, Pournaras S, TseliotiP, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with blood stream infections caused by KPC‑producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17:1798‑803. 37. DaikosGL, TsaousiS, TzouvelekisLS, AnyfantisI, PsichogiouM, Argyropoulou A, et al. Carbapenemase‑producing Klebsiella pneumoniae blood stream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58:2322‑8. 38. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended‑spectrum beta‑lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta‑analysis. J Antimicrob Chemother 2007;60:913‑20. 39. Balkan II, Aygün G, Aydin S, Mutcali SI, Kara Z, Kuskucu M, et al. Blood stream infections due to OXA‑48‑like carbapenemase‑producing Enterobacteriaceae: Treatment and survival. Int J Infect Dis 2014;26:51‑6. 40. Kalanuria AA, Zai W, Mirski M. Ventilator‑associated pneumonia in the ICU. Crit Care 2014;18:208. 41. Garnacho‑Montero J, Corcia‑Palomo Y, Amaya‑Villar R, Martin‑Villen L. How to treat VAP due to MDR pathogens in ICU patients. BMC Infect Dis 2014;14:135. 42. Naesens R, Vlieghe E, Verbrugghe W, Jorens P, Ieven M. A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug‑resistant Pseudomonas aeruginosa. BMC Infect Dis 2011;11:317. 43. Gu WJ, Wang F, Tang L, Bakker J, Liu JC. Colistin for the treatment of ventilator‑associated pneumonia caused by multidrug‑resistant Gram‑negative bacteria: A systematic review and meta‑analysis. Int J Antimicrob Agents 2014;44:477‑85. 44. Ye JJ, Lin HS, Kuo AJ, Leu HS, Chiang PC, Huang CT, et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug‑resistant Acinetobacter baumannii. J Infect 2011;63:351‑61. 45. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, et al. Effect of sulbactam on infections caused by imipenem‑resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448‑51. 46. Garnacho‑Montero J, Ortiz‑Leyba C, Jiménez‑Jiménez FJ, Barrero‑Almodóvar AE, García‑Garmendia J L , Bernabeu‑WittelI M, et al. Treatment of multidrug‑resistant Acinetobacter baumannii v e n t i l a t o r ‑ a s s o c i a t e d pneumonia (VAP) with intravenous colistin: A comparison with imipenem‑susceptible VAP. Clin Infect Dis 2003;36:1111‑8. 47. Wood GC, Hanes SD, Boucher BA, Croce MA, Fabian TC. Tetracyclines for treating multidrug‑resistant Acinetobacter baumannii ventilator‑associated pneumonia. Intensive Care Med 2003;29:2072‑6. 48. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan‑drug resistant Acinetobacter baumannii. Scand J Infect Dis 2005;37:195‑9. 49. Petrosillo N, Chinello P, Proietti MF, Cecchini L, Masala M, Franchi C, et al. Combined colistin and rifampicin therapy for carbapenem‑resistant Acinetobacter baumannii infections: Clinical outcome and adverse events. Clin Microbiol Infect 2005;11:682‑3. 50. Bassetti M, Repetto E, Righi E, Boni S, Diverio M, Molinari MP, et al. Colistin and rifampicin in the treatment of multidrug‑resistant Acinetobacter baumannii infections. J Antimicrob Chemother 2008;61:417‑20. 51. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High‑dose ampicillin‑sulbactam as an alternative treatment of late‑onset VAP from multidrug‑resistant Acinetobacter baumannii. Scand J Infect Dis 2007;39:38‑43. 52. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, Aydemir S, Bacakoglu F. Is tigecyclin a good choice in the treatment of multidrug‑resistant Acinetobacter baumannii pneumonia? J Chemother 2011;23:345‑9. 53. Shields RK, Clancy CJ, Gillis LM, Kwak EJ, Silveira FP, Massih RC, et al. Epidemiology, clinical characteristics and outcomes of extensively drug‑resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 2012;7:e52349. 54. Durante‑Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug‑resistant Acinetobacter baumannii: A multicenter, randomized clinical trial. Clin Infect Dis 2013;57:349‑58. 55. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M. Use of high‑dose IV and aerosolized colistin for the treatment of multidrug‑resistant Acinetobacter baumannii ventilator‑associated pneumonia: Do we really need this treatment? J Infect Chemother 2012;18:872‑7. 56. McLaughlin MM, Advincula MR, Malczynski M, Barajas G, Qi C, Scheetz MH. Quantifying the clinical virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae with a Galleria mellonella model and a pilot study to translate to patient outcomes. BMC Infect Dis 2014;14:31. 57. Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, et al. Effectiveness of tigecycline‑based versus colistin‑based therapy for treatment of pneumonia caused by multidrug‑resistant Acinetobacter baumannii in a critical setting: A matched cohort analysis. BMC Infect Dis 2014;14:102. 58. Krol V, Hamid NS, Cunha BA. Neurosurgically related nosocomial Acinetobacter baumannii meningitis: Report of two cases and literature review. J Hosp Infect 2009;71:176‑80. 59. Wroblewska MM, Dijkshoorn L, Marchel H, van den Barselaar M, Swoboda‑Kopec E, van den Broek PJ, et al. Outbreak of nosocomial meningitis caused by Acinetobacter baumannii in neurosurgical patients. J Hosp Infect 2004;57:300‑7. 60. Nagaveni S, Rajeshwari H, OliAK, Patil SA, ChandrakanthRK. Widespread emergence of multidrug resistant Pseudomonas aeruginosa isolated from CSF samples. Indian J Microbiol 2011;51:2‑7. 61. van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet 2012;380:1693‑702. 62. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sadoh S, Kobayashi T, et al. Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post‑neurosurgical bacterial meningitis. Scand J Infect Dis 2011;43:982‑5. 63. Di Paolo A, Gori G, Tascini C, Danesi R, Del Tacca M. Clinical pharmacokinetics of antibacterials in cerebrospinal fluid. Clin Pharmacokinet 2013;52:511‑42. 64. Rodríguez Guardado A, Blanco A, Asensi V, Pérez F, Rial JC, Pintado V, et al. Multidrug‑resistant Acinetobacter meningitis in neurosurgical patients with intraventricular catheters: Assessment of different treatments. J Antimicrob Chemother 2008;61:908‑13. 65. CascioA, ContiA, Sinardi L, Iaria C, Angileri FF, Stassi G, et al. Post‑neurosurgical multidrug‑resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis 2010;14:e572‑9. 66. Imberti R, Cusato M, Accetta G, Marinò V, Procaccio F, Del Gaudio A, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother 2012;56:4416‑21. 67. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram‑negative meningitis: A systematic review of the available evidence. Int J Antimicrob Agents 2007;29:9‑25. 68. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug‑resistant Acinetobacter baumannii central nervous system infection: A case series and systematic review. Clin Microbiol Infect 2010;16:888‑94. 69. MarkantonisSL, MarkouN, FousteriM, SakellaridisN, KaratzasS, Alamanos I, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009;53:4907‑10. 70. Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug‑resistant and extensively drug‑resistant Acinetobacter baumannii ventriculitis and meningitis: A literature review. Int J Antimicrob Agents 2013;41:499‑508. 71. Georges H, Chiche A, Alfandari S, Devos P, Boussekey N, Leroy O. Adult community‑acquired bacterial meningitis requiring ICU admission: Epidemiological data, prognosis factors and adherence to IDSA guidelines. Eur J Clin Microbiol Infect Dis 2009;28:1317‑25. 72. Rodríguez‑Baño J, Martí S, Soto S, Fernández‑Cuenca F, Cisneros JM, Pachón J, et al. Biofilm formation in Acinetobacter baumannii: Associated features and clinical implications. Clin Microbiol Infect 2008;14:276‑8. 73. Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic‑resistant Acinetobacter species. Lancet Infect Dis 2009;9:245‑55. 74. Levison ME, Kaye D. Treatment of complicated urinary tract infections with an emphasis on drug‑resistant gram‑negative uropathogens. Curr Infect Dis Rep 2013;15:109‑15. 75. Takeyama K, Kunishima Y, Matsukawa M, Takahashi S, Hirose T, Kobayashi N, et al. Multidrug‑resistant Pseudomonas aeruginosa isolated from the urine of patients with urinary tract infection. J Infect Chemother 2002;8:59‑63. 76. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM Jr, Ritchie DJ. Treatment and clinical outcomes of urinary tract infections caused by KPC‑producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012;34:1314‑23. 77. Volkow‑Fernández P, Rodríguez CF, Cornejo‑Juárez P. Intravesical colistin irrigation to treat multidrug‑resistant Acinetobacter baumannii urinary tract infection: A case report. J Med Case Rep 2012;6:426. 78. Rafailidis PI, Falagas ME. Options for treating carbapenem‑resistant Enterobacteriaceae. Curr Opin Infect Dis 2014;27:479‑83. 79. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug‑resistant Gram‑negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53‑9
Mandana Izadpanah,.. and Hossein Khalili,.. (2015). Antibiotic regimens for treatment of infections due to multidrug‑resistant Gram‑negative pathogens: An evidence‑based literature review. Journal of Research in Pharmacy Practice, 4(3), 105-114.
MLA
Mandana Izadpanah,.. , and Hossein Khalili,.. . "Antibiotic regimens for treatment of infections due to multidrug‑resistant Gram‑negative pathogens: An evidence‑based literature review", Journal of Research in Pharmacy Practice, 4, 3, 2015, 105-114.
HARVARD
Mandana Izadpanah .., Hossein Khalili .. (2015). 'Antibiotic regimens for treatment of infections due to multidrug‑resistant Gram‑negative pathogens: An evidence‑based literature review', Journal of Research in Pharmacy Practice, 4(3), pp. 105-114.
CHICAGO
.. Mandana Izadpanah and .. Hossein Khalili, "Antibiotic regimens for treatment of infections due to multidrug‑resistant Gram‑negative pathogens: An evidence‑based literature review," Journal of Research in Pharmacy Practice, 4 3 (2015): 105-114,
VANCOUVER
Mandana Izadpanah .., Hossein Khalili .. Antibiotic regimens for treatment of infections due to multidrug‑resistant Gram‑negative pathogens: An evidence‑based literature review. Journal of Research in Pharmacy Practice, 2015; 4(3): 105-114.
